Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease
Low-dose aspirin (75-100 mg daily) might be considered for select adults aged 40-70 years with ≥10% 10-year ASCVD risk who lack increased bleeding risk, but it should NOT be routinely used in adults over 70 years or anyone with elevated bleeding risk. 1, 2
Who May Benefit: Specific Criteria
The evidence supports aspirin use ONLY when ALL of the following conditions are met:
Age 50-59 Years (Strongest Recommendation)
- 10-year ASCVD risk ≥10% (calculate using ACC/AHA Pooled Cohort Equations)
- No increased bleeding risk (see contraindications below)
- Life expectancy ≥10 years
- Willing to take aspirin daily for ≥10 years
- This is a Grade B recommendation from USPSTF 2
Age 60-69 Years (Individualized Decision)
- Same criteria as above, but the decision requires shared decision-making
- Benefits are smaller and less certain in this age group
- Only proceed if patient values potential benefits over harms
- This is a Grade C recommendation 2
Age 40-49 Years
- May be considered in select higher-risk individuals (Class IIb recommendation) 1
- Evidence is weaker; requires careful risk-benefit assessment
Absolute Contraindications
Do NOT use aspirin for primary prevention in:
Age-Based Exclusions
- Adults >70 years - bleeding risk outweighs benefits (Class III: Harm) 1
- Insufficient evidence for those <40 years 2
Bleeding Risk Factors (Class III: Harm) 1, 3
- Age ≥60 years with bleeding history
- History of peptic ulcer disease or GI bleeding
- Concurrent anticoagulation (warfarin, DOACs)
- Concurrent NSAID use (ibuprofen, naproxen)
- ≥3 alcoholic drinks daily
- Uncontrolled hypertension
- Thrombocytopenia or bleeding disorders
Other Contraindications 3
- Aspirin allergy (may cause hives, facial swelling, asthma, shock)
- Last trimester of pregnancy (may cause fetal complications or delivery problems)
- Children/teenagers with viral illnesses (Reye's syndrome risk)
Key Evidence Nuances
The 2018-2019 Paradigm Shift
Recent major trials (ASPREE, ASCEND, ARRIVE) fundamentally changed aspirin's role 4, 5:
- ASPREE: In elderly patients, aspirin showed no benefit but increased major hemorrhage and unexpectedly increased all-cause mortality
- ASCEND: In diabetics, aspirin reduced vascular events but equally increased major bleeding
- ARRIVE: In moderate-risk patients, no cardiovascular benefit but increased GI bleeding
The net result: aspirin's cardiovascular benefits are now considered equally balanced by bleeding harms in most primary prevention scenarios 6, 7
Special Populations
Diabetes Mellitus:
- Consider aspirin only if 10-year CVD risk >10% AND no increased bleeding risk 2
- The ASCEND trial showed equal benefits and harms 4
Advanced Subclinical Atherosclerosis:
- Patients with high coronary artery calcium scores or significant carotid plaque may derive greater benefit 8, 9
- This represents a higher-risk subset where benefits may outweigh harms
- Not extensively studied in trials but supported by post-hoc analyses
Dosing
- 75-100 mg orally daily 1, 2
- Lower doses within this range (75-81 mg) may reduce bleeding risk while maintaining efficacy
Critical Pitfalls to Avoid
- Do not prescribe aspirin based solely on age or single risk factor - must calculate formal 10-year ASCVD risk
- Do not ignore bleeding risk assessment - the FDA specifically denied approval for primary prevention due to bleeding concerns 2
- Do not use in patients >70 years - this is now explicitly contraindicated in guidelines 1
- Do not combine with other NSAIDs or anticoagulants without compelling indication 3
- Do not assume "low-dose" means "low-risk" - even 75-100 mg increases major bleeding by 42% (RR 1.42) 6
The Bottom Line
The 2019 ACC/AHA guidelines downgraded aspirin to Class IIb ("might be considered") for ages 40-70 with high ASCVD risk, and Class III: Harm (contraindicated) for those >70 years or with bleeding risk 1. This represents a major shift from historical practice. The contemporary evidence shows aspirin's cardiovascular benefits in primary prevention are modest and largely offset by bleeding complications 6, 5, 7. Use should be highly selective, limited to patients aged 40-70 years with ≥10% 10-year ASCVD risk, no bleeding risk factors, and willingness for long-term therapy.